Successful Dostarlimab Rechallenge Following Pembrolizumab‐Induced Autoimmune Hemolytic Anemia: A Case Report

Successful Dostarlimab Rechallenge Following Pembrolizumab‐Induced Autoimmune Hemolytic Anemia: A Case Report

ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, offering durable responses across multiple malignancies. However, these agents can trigger severe immune‐related adverse events (irAEs), including drug‐induced autoimmune hemolytic anemia (AIHA), which often necessita...

Full description

Saved in:
Bibliographic Details
Main Authors: Zaid Khamis, Kai Wang, Mohammad Aldalahmeh, Salim Barakat, Nawaraj Adhikari, Raghad Khassawneh, Bhavya Misri, Dhar Meekoo
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:Clinical Case Reports
Subjects:
adverse immune events
autoimmune hemolytic anemia
checkpoint inhibitor rechallenge
dostarlimab
immune checkpoint inhibitors
pembrolizumab
Online Access:https://doi.org/10.1002/ccr3.70776
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items